Press Releases

March 23, 2017
FDA Provides Cornerstone Pharmaceuticals Approval to Initiate Pivotal Study for CPI-613, its Metabolism-Directed Anticancer Compound

February 08, 2017
Cornerstone Pharmaceuticals, Inc. Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards

January 10, 2017
Cornerstone Pharmaceuticals, Inc. Announces Additions to its Board of Directors: Jean-Pierre Sommadossi, Ph.D., Richard Axel, M.D., Chi Van Dang, M.D., Ph.D., and Richard Scheller, Ph.D.

December 22, 2016
Cornerstone Pharmaceuticals to Present at 9th Annual Biotech Showcase™ in San Francisco, January 9-11, 2017

December 05, 2016
Cornerstone Pharmaceuticals, Inc. Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin’s Lymphoma (T-cell NHL) at ASH 2016

November 29, 2016
Cornerstone Pharmaceuticals Appoints Brian Mullaney, M.D., Ph.D., as Chief Medical Officer

November 21, 2016
Cornerstone Pharmaceuticals to Present New Data on CPI-613 at the American Society of Hematology 2016 Annual Meeting

November 10, 2016
IDT Corporation Announces Investment in Cornerstone Pharmaceuticals

October 06, 2016
European Society for Medical Oncology (ESMO) Congress 2016 has Accepted the Abstract on Phase I Trial of CPI-613 in Combination with Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin (mFOLFIRINOX) in First Line Patients with Metastatic Pancreatic Adenocarcinoma

September 26, 2016
Cornerstone Pharmaceuticals Inc at Ladenburg Thalmann 2016 Healthcare Conference
Event Details: Tuesday, September 27, 2016

February 05, 2016
Cornerstone Pharmaceuticals Inc at Leerink Partners 5th Annual Global Healthcare Conference
Event Details: Wednesday, February 10, 2016 11:55 a.m. ET

January 22, 2016
Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin (mFOLFIRINOX) in Metastatic Pancreatic Adenocarcinoma to Be Presented at the Annual Gastrointestinal Cancers Symposium

November 23, 2015
Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone in Relapsed or Refractory Acute Myeloid Leukemia to Be Presented at 57th Annual ASH Meeting

January 21, 2015
Cornerstone Pharmaceuticals Receives Funding through New Jersey’s Technology Business Tax Certificate Transfer Program

January 12, 2015
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Metastatic Colorectal Cancer

December 05, 2014
Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613 for the Treatment of B-Cell Non-Hodgkin Lymphoma

November 13, 2014
Cornerstone Pharmaceuticals’ CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting Oncology Projects to Watch

November 06, 2014
Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be Presented at 2014 ASH Annual Meeting

October 21, 2014
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin’s or T-Cell Non-Hodgkin’s Lymphoma

October 09, 2014
Cornerstone Pharmaceuticals Appoints Steve Carchedi Chief Executive Officer

October 07, 2014
Cornerstone Pharmaceuticals’ CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR’s Clinical Cancer Research

May 14, 2014
Cornerstone Pharmaceuticals Clinical Data on CPI-613 to be Presented at ASCO 2014

April 18, 2014
Cornerstone Pharmaceuticals’ CPI-613 Data to be Presented at the 2014 Annual American Society of Clinical Oncology (ASCO) Meeting